Introduction: A tumor microenvironment plays an important role in bladder cancer development and in treatment response. Purpose: The aim of the study was to assess how the components of the microenvironment affect tumor recurrence and to find the potential biomarkers for immunotherapy in NMIBC. Methods: The study group consisted of 55 patients with primary NMIBC. Immunohistochemistry was performed on sections of primary papillary urothelial carcinoma of the bladder. Cox proportional hazard multiple regression analysis was performed to characterize tumors with the highest probability of an unfavorable outcome. Results: Multivariate analysis confirmed that the CD4 (p = 0.001), CD20 (p = 0.008) and PD-L1 expressed on tumor cells (p = 0.01) were independently associated with the risk of recurrence of bladder cancer. Patients with weak CD4+ cell infiltration (10%) belong to the group with a lower risk of recurrence. The cancer in this group also frequently recurs after 12 months (p = 0.0005). Conclusions: The evaluation of CD4+ and CD20+ cells in the tumor microenvironment, in addition to PD-L1 on tumor cells, facilitates the determination of a group of patients with a low risk of recurrence.
Introduction A tumor microenvironment plays an important role in bladder cancer development as well as in a treatment response. Purpose The aim of the study is to assess how the components of the microenvironment, in terms of cells, potentially affect tumor recurrence as well as to find the potential biomarkers for immunotherapy in NMIBC. Methods The study group consisted of 55 patients with primary NMIBC. Immunohistochemistry was performed on sections of primary papillary urothelial carcinoma of the bladder removed during transurethral resection of the tumor. Cox proportional hazard multiple regression analysis was performed to characterize tumors with the highest probability of an unfavorable outcome. Results The expression of analyzed variables was found in 90% of the examined tissues. Multivariate analysis confirmed that the CD4 (HR 1.19, 95% CI 1.07-1.32, p = 0.001), CD20 (HR 0.9, 95% CI 0.84-0.97, p = 0.008) and PD-L1 expressed on tumor cells (HR 0.05, 95% CI 0.008-0.29, p = 0.01) were independently associated with the risk of recurrence of bladder cancer. Patients with weak CD4+ cells (< 4,6%)infiltration andsevere CD20+ infiltration (>10%) belong to the group with a lower risk of recurrence. The cancer in this group frequently recurs also after 12 months (p=0.0005). Conclusions The evaluation of CD4+ and CD20+ cells in the tumor microenvironment, in addition to PD-L1 on tumor cells, facilitates determination of a group of patients with a low risk of the recurrence that could also be recognized after 12 months following the primary tumor resection.
Background/Objectives: In recent years, growing evidence that the tumor microenvironment (TME) plays crucial roles in the progression and treatment responses of various cancers has emerged. Unfortunately, we still do not fully understand the mechanisms through which the TME influences cancer development. Therefore, the aim of this study is to assess the impact of the TME on the clinical course of the disease, comparing primary and metastatic tumors. Materials and Methods: This retrospective study included 30 colorectal cancer patients for which tissue samples from primary and metastatic tumors were available for immunohistochemistry. A multiple Cox proportional hazards regression analysis was performed to characterize differences between the microenvironments of primary and metastatic tumors, as well as between lesions diagnosed at different times after resection. Results: Immune cell infiltration was higher in metastatic than primary tumors. Statistically significant differences were observed only in the central part of the tumor, while cell infiltration at the periphery had no prognostic significance. In the multivariate analysis, a positive correlation was revealed between the expression of Programmed Death-Ligand 1 (PD-L1) on primary tumor cells (TCs) and survival (HR: 5.43; 95% CI: 1.89–15.61; p = 0.0017). Conclusions: Primary and metastatic tumors differ regarding their tumor microenvironment. As such, the tumor immune status should be considered as a key factor when selecting a therapeutic strategy, as well as for post-treatment surveillance.